相关实验视频

Updated: May 7, 2026

Remote Limb Ischemic Preconditioning: A Neuroprotective Technique in Rodents

Remote Limb Ischemic Preconditioning: A Neuroprotective Technique in Rodents

Published on: June 2, 2015

在死角性肠球炎中进行远程缺血调节:一项扩展的第一阶段安全研究

Yongfang Wu¹, Niloofar Ganji², Zhou Chen³

¹Neonatal Medical Center, Children's Hospital of Fudan University (Xiamen Branch), Xiamen Children's Hospital, Fujian, 361006, China.

Pediatric surgery international

|December 20, 2025

概括

远程缺血调节 (RIC) 对早产儿患有死角性肠球炎 (NEC) 是安全的. 这项研究证实了RIC在新生儿中的安全性,即使在医疗和外科NEC病例中应用范围扩大.

科学领域:

新生儿医学新生儿医学
儿科手术儿科手术
关键的护理关键的护理

背景情况:

结核性肠球炎 (NEC) 是早产婴儿的一种严重疾病.
远程缺血调节 (RIC) 显示出作为NEC的新型治疗策略的潜力.
之前的试验表明,RIC在患有NEC的人类早产新生儿中安全.

研究的目的:

进一步评估RIC在被诊断为NEC的早产婴儿中延长应用的安全性.
评估主要终点是输液在RIC干预后5分钟内恢复到基线.
评估二次终点,包括皮肤损伤和疼痛得分.

主要方法:

一个单一中心,第一阶段,非随机试验进行.
有确定的NEC的早产婴儿 (<36周妊娠年龄) 接受了RIC干预.
RIC涉及连续两天的四个5分钟缺血-再输血周期.

主要成果:

招募了6名患有NEC的早产新生儿,并完成了RIC干预.
所有新生儿的动脉流量正常,肢体输液在干预后5分钟内恢复到基线.
没有观察到新的皮肤病变或疼痛评分 (PIPP) 的显著差异.

结论:

远程缺血调节 (RIC) 使用5分钟的缺血-再输循环是NEC早产婴儿的安全干预措施.
在极度早产的新生儿中,RIC在长期应用时是安全的,具有医疗和外科NEC.

关键词:

死性肠道结肠炎 (NECO) 是一种远程缺血调节的条件是远程缺血.安全性研究安全性研究

更多相关视频

Experimental Models to Study the Neuroprotection of Acidic Postconditioning Against Cerebral Ischemia

Experimental Models to Study the Neuroprotection of Acidic Postconditioning Against Cerebral Ischemia

Published on: July 31, 2017

Author Spotlight: A Novel Standardized Technique for Real-Time Biomedical Imaging of Acute Myocardial Injury

Author Spotlight: A Novel Standardized Technique for Real-Time Biomedical Imaging of Acute Myocardial Injury

Published on: March 22, 2024

相关概念视频

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.